If regenerative neurology restores function, it will meet a huge unmet need and change dogma
Treatment of stroke in the acute phase has come a long way with the development of paramedic, emergency department and stroke team pathways for hyperacute assessment and management with intravenous thrombolysis, endovascular clot retrieval and hemicraniectomy. Acute stroke units reduce mortality and morbidity by up to 20% or more.1 An estimated 80% of stroke patients survive for one year after stroke, with the large majority being left with chronic disability.2 In Australia and many other countries around the world, stroke is the leading cause of adult disability.3 It is estimated that up to 450 000 Australians have disability after stroke.4,5
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Hamann GF, Müller R, Alber B, Widder B. Treatment in acute stroke — stroke unit is mandatory. Neurol Psychiatry Brain Res 2016; 22: 105-109.
- 2. Gloede TD, Halbach SM, Thrift AG, et al. Long-term costs of stroke using 10-year longitudinal data from the North East Melbourne Stroke Incidence Study. Stroke 2014; 45: 3389.
- 3. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2014; 383: 245-254.
- 4. Australian Institute of Health and Welfare. Stroke and its management in Australia: an update (AIHW Cat. No. CVD 61; Cardiovascular Disease Series No. 37). Canberra: AIHW, 2013. http://www.aihw.gov.au/publication-detail/?id=60129543613 (accessed Mar 2017).
- 5. Deloitte Access Economics. The economic impact of stroke in Australia. National Stroke Foundation 13 March 2013. Canberra: Deloitte Access Economics, 2013. http://www.deloitteaccesseconomics.com.au/uploads/File/Stroke%20Report%2014%20Mar%2013.pdf (accessed Jan 2017).
- 6. Pollock A, Baer G, Campbell P, et al. Physical rehabilitation approaches for the recovery of function and mobility following stroke. Cochrane Database Syst Rev 2014; (4): CD001920.
- 7. Langhorne P, Bernhardt J, Kwakkel G. Stroke rehabilitation. Lancet 2011; 377: 1693-1702.
- 8. Polak JM, Mantalaris S. Stem cells bioprocessing: an important milestone to move regenerative medicine research into the clinical arena. Pediatr Res 2008; 63: 461-466.
- 9. Leong WK, Lewis MD, Koblar SA. Concise review: preclinical studies on human cell-based therapy in rodent ischemic stroke models: where are we now after a decade? Stem Cells 2013; 31: 1040-1043.
- 10. Kalladka D, Muir KW. Brain repair: cell therapy in stroke. Stem Cells Cloning 2014; 7: 31-44.
- 11. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-176.
- 12. ClinicalTrials.gov. 57 studies found for: Induced pluripotent stem cell. https://clinicaltrials.gov/ct2/results?term=Induced+pluripotent+stem+cell&type=&rslt=&recr=&age_v=&gndr=&cond=&intr=&titles=&outc=&spons=&lead=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&rcv_s=&rcv_e=&lup_s=&lup_e= (accessed Mar 2017).
- 13. Eckert A, Huang L, Gonzalez R, et al. Bystander effect fuels human induced pluripotent stem cell-derived neural stem cells to quickly attenuate early stage neurological deficits after stroke. Stem Cells Transl Med 2015; 4: 841-851.
- 14. Zents K, Copray S. The therapeutic potential of induced pluripotent stem cells after stroke: evidence from rodent models. Curr Stem Cell Res Ther 2016; 11: 166-174.
- 15. Chang DJ, Lee N, Park IH, et al. Therapeutic potential of human induced pluripotent stem cells in experimental stroke. Cell Transplant 2013; 22: 1427-1440.
- 16. Kalladka D, Sinden J, Pollock K, et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. Lancet 2016; 388: 787-796.
- 17. Steinberg GK, Kondziolka D, Wechsler LR, et al. Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke: a Phase 1/2a study. Stroke 2016; 47: 1817-1824.
- 18. Muir KW. Clinical trial design for stem cell therapies in stroke: what have we learned? Neurochem Int 2016; doi: 10.1016/j.neuint.2016.09.011 [Epub ahead of print].
- 19. Kenmuir CL, Reddy VK, Mountz J, et al. Changes in FDG-PET activity following intraparenchymal injection of SB623 cells in patients with stable ischemic strokes [abstract]. Stroke 2015; 46: AWMP93.
- 20. Rodríguez-Frutos B, Otero-Ortega L, Gutiérrez-Fernández M, et al. Stem cell therapy and administration routes after stroke. Transl Stroke Res 2016; 7: 378-387.
- 21. Nagpal A, Kremer KL, Hamilton-Bruce MA, et al. TOOTH (The Open study Of dental pulp stem cell Therapy in Humans): study protocol for evaluating safety and feasibility of autologous human adult dental pulp stem cell therapy in patients with chronic disability after stroke. Int J Stroke 2016; 11: 575-585.
- 22. Savitz SI, Cramer SC, Wechsler L, et al. Stem cells as an emerging paradigm in stroke 3 enhancing the development of clinical trials. Stroke 2014; 45: 634-639.
- 23. Lees JS, Sena ES, Egan KJ, et al. Stem cell-based therapy for experimental stroke: a systematic review and meta-analysis. Int J Stroke 2012; 7: 582-588.
- 24. Munsie M, Pera, M. Regulatory loophole enables unproven autologous cell therapies to thrive in Australia. Stem Cells Dev 2014; 23 Suppl 1: 34-38.
- 25. Konomi K TM, Kimura K, Sato D. New Japanese initiatives on stem cell therapies. Cell Stem Cell 2015; 16: 350-352.
- 26. Nagpal A, Juttner C, Hamilton-Bruce MA, et al. Stem cell therapy clinical research: A regulatory conundrum for academia. Advanced Drug Delivery Rev 2016; DOI: 10.1016/j.addr.2016.10.001 [Epub ahead of print].
Online responses are no longer available. Please refer to our instructions for authors page for more information.
No relevant disclosures.